Back to Map
RECRUITING
Updated: Feb 5, 2026
Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
Brief Summary
The purpose of this research is (1) to identify disease specific walking-related digital biomarkers of disease severity, and (2) monitor longitudinal changes in natural environments, for extended periods of time, in DMD and SMA.
Key Information
Participation Criteria
Study Design
Locations & Contacts
Inclusion Criteria:
- Genetic confirmation of disease (DMD, SMA) or healthy control
- Able to walk independently at least 25 meters
- Ongoing corticosteroids therapy or initiation of corticosteroid therapy in the previous 3 months for DMD
- Stable dose of FDA approved SMN up-regulator therapy or in an open-label extension phase of a study treatment for at least 6 months for SMA or gene replacement at enrollment for SMA or DMD participants.
Exclusion Criteria:
- Use foot orthoses or assistive devices for community ambulation or a mobility device for community navigation
- Use investigational medications intended for treatment of NMD within 30 days
- Prior to study entry had an injury or surgery that would impact gait within the previous 3 months